Autoimmune Cardiotoxicity of Cancer Immunotherapy

Feixiong Cheng; Joseph Loscalzo

doi:10.1016/j.it.2016.11.007

Autoimmune Cardiotoxicity of Cancer Immunotherapy

Trends Immunol. 2017 Feb;38(2):77-78. doi: 10.1016/j.it.2016.11.007. Epub 2016 Dec 2.

Authors

Feixiong Cheng¹, Joseph Loscalzo²

Affiliations

¹ Center for Complex Networks Research, Northeastern University, Boston, MA 02115, USA; Center for Cancer Systems Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address: [email protected].
² Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA. Electronic address: [email protected].

PMID: 27919707
DOI: 10.1016/j.it.2016.11.007

Abstract

Contemporary immunotherapies (e.g., immune checkpoint inhibitors), which enhance the immune response to cancer cells, improve clinical outcomes in several malignancies. A recent study reported the cases of two patients with metastatic melanoma who developed fatal myocarditis during ipilimumab and nivolumab combination immunotherapy; these examples highlight the risk of unbridled activation of the immune system.

Keywords: cardio-oncology; immune checkpoint; immunotherapy.; ipilimumab; nivolumab.

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Autoimmune Diseases / etiology
Autoimmune Diseases / immunology*
Costimulatory and Inhibitory T-Cell Receptors / antagonists & inhibitors
Costimulatory and Inhibitory T-Cell Receptors / immunology
Humans
Immunotherapy / adverse effects
Immunotherapy / methods*
Ipilimumab
Myocarditis / etiology
Myocarditis / immunology*
Neoplasms / immunology
Neoplasms / therapy*
Nivolumab
Risk

Substances

Antibodies, Monoclonal
Costimulatory and Inhibitory T-Cell Receptors
Ipilimumab
Nivolumab